Therapeutic effect of TTR siRNA on hereditary transthyretin amyloidosis (ATTRv) nephropathy
We demonstrated that TTR siRNA therapeutics represent potential candidates for ATTRv nephropathy, despite the fact that their use has been limited to neurological symptoms to date.
Authors
- Yoshitaka Isaka (ORCID: https://orcid.org/0000-0002-0820-7167)
- Jun Matsuda (ORCID: https://orcid.org/0000-0003-1492-6157)
- Fusako Sera
- Hiroaki Yonishi (ORCID: https://orcid.org/0000-0002-0529-9350)
- Hideki Mochizuki (ORCID: https://orcid.org/0000-0002-0874-7542)
- Keita Kakuda (ORCID: https://orcid.org/0000-0003-2563-5443)
- Yasushi Sakata (ORCID: https://orcid.org/0000-0002-5618-4721)
- Yumiko Yasuhara (ORCID: https://orcid.org/0000-0003-4391-186X)
- Tatsuhiko Ozono (ORCID: https://orcid.org/0000-0002-0439-6183)
- Kensuke Ikenaka (ORCID: https://orcid.org/0000-0002-5559-1966)
- Takahiro Ajiki
- César Aguirre
Institutions
- Sakai Municipal Hospital (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Amyloid
- Published
- 2025-02-23
- DOI
- https://doi.org/10.1080/13506129.2025.2470369
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00